GT201400031A - Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 - Google Patents

Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2

Info

Publication number
GT201400031A
GT201400031A GT201400031A GT201400031A GT201400031A GT 201400031 A GT201400031 A GT 201400031A GT 201400031 A GT201400031 A GT 201400031A GT 201400031 A GT201400031 A GT 201400031A GT 201400031 A GT201400031 A GT 201400031A
Authority
GT
Guatemala
Prior art keywords
bace
oxazine
derivatives
piridin
dihidro
Prior art date
Application number
GT201400031A
Other languages
English (en)
Inventor
Lueoend Rainer Martin
Machauer Rainer
Rueeger Heinrich
Veenstra Siem Jacob
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of GT201400031A publication Critical patent/GT201400031A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE OXAZINA DE FÓRMULA (I), Y SALES FARMACÉUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LOS QUE TODAS LAS VARIABLES SON COMO SE DEFINEN EN LA ESPECIFICACIÓN, COMPOSICIONES FARMACÉUTICAS DE LOS MISMOS, COMBINACIONES DE LOS MISMOS, Y SU USO COMO MEDICAMENTOS, PARTICULARMENTE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER O LA DIABETES A TRAVÉS DE LA INHIBICIÓN DE BACE-1 O BACE-2.
GT201400031A 2011-08-25 2014-02-24 Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2 GT201400031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161527172P 2011-08-25 2011-08-25
US201261665395P 2012-06-28 2012-06-28

Publications (1)

Publication Number Publication Date
GT201400031A true GT201400031A (es) 2015-02-19

Family

ID=47018309

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400031A GT201400031A (es) 2011-08-25 2014-02-24 Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2

Country Status (28)

Country Link
US (2) US9163011B2 (es)
EP (2) EP2748162B1 (es)
JP (1) JP5816369B2 (es)
KR (1) KR101601571B1 (es)
CN (1) CN103906748B (es)
AP (1) AP2014007507A0 (es)
AR (1) AR087668A1 (es)
AU (1) AU2012298177B2 (es)
BR (1) BR112014004131A2 (es)
CA (1) CA2845093A1 (es)
CL (1) CL2014000458A1 (es)
CO (1) CO6890097A2 (es)
CR (1) CR20140084A (es)
EA (1) EA024580B1 (es)
ES (2) ES2638832T3 (es)
GT (1) GT201400031A (es)
HK (1) HK1195903A1 (es)
IL (1) IL230975A0 (es)
MA (1) MA35356B1 (es)
MX (1) MX339303B (es)
PE (1) PE20141540A1 (es)
PL (1) PL2748162T3 (es)
SG (1) SG2014012108A (es)
TN (1) TN2014000062A1 (es)
TW (1) TW201313706A (es)
UY (1) UY34278A (es)
WO (1) WO2013027188A1 (es)
ZA (1) ZA201401139B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009258496B8 (en) 2008-06-13 2014-06-26 Shionogi & Co., Ltd. Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
EA024059B1 (ru) 2011-01-13 2016-08-31 Новартис Аг Гетероциклические производные и их применение в лечении неврологических расстройств
WO2014065434A1 (en) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having bace1 inhibitory activity
US9296734B2 (en) 2013-03-01 2016-03-29 Amgen Inc. Perfluorinated 5,6-dihydro-4H-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
SG11201507196WA (en) 2013-03-08 2015-10-29 Amgen Inc Perfluorinated cyclopropyl fused 1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
BR112015019412A8 (pt) * 2013-04-11 2019-11-12 Hoffmann La Roche inibidores de bace1, seus usos, e composição farmacêutica
TWI639607B (zh) 2013-06-18 2018-11-01 美國禮來大藥廠 Ｂａｃｅ抑制劑
UA117695C2 (uk) * 2014-02-19 2018-09-10 Х. Луннбек А/С 2-аміно-3,5,5-трифтор-3,4,5,6-тетрагідропіридини як інгібітори bace1 для лікування хвороби альцгеймера
TW201623295A (zh) 2014-04-11 2016-07-01 塩野義製藥股份有限公司 具有ｂａｃｅ１抑制活性之二氫噻及二氫衍生物
WO2016022724A1 (en) 2014-08-08 2016-02-11 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
DK3261721T3 (da) * 2015-02-25 2022-11-28 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til forbedring af hukommelse
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
KR20180033524A (ko) 2015-08-12 2018-04-03 하. 룬드벡 아크티에셀스카브 Bace1 저해제로서의 2-아미노-3-플루오로-3-(플루오로메틸)-6-메틸-6-페닐-3,4,5,6-테트라하이드로피리딘
CN108699051B (zh) * 2016-03-01 2021-12-24 豪夫迈·罗氏有限公司 Bace1抑制剂
MA54101A (fr) 2016-12-15 2021-10-27 Amgen Inc Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
JP7149271B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としての１，４－チアジンジオキシドおよび１，２，４－チアジアジンジオキシド誘導体ならびに使用方法
AU2017378316B2 (en) 2016-12-15 2021-04-01 Amgen Inc. Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use
MX2019007101A (es) * 2016-12-15 2019-12-16 Amgen Inc Derivados de oxazina como inhibidores de beta secretasa y metodos de uso.
JP7149272B2 (ja) 2016-12-15 2022-10-06 アムジエン・インコーポレーテツド β－セクレターゼ阻害剤としてのチアジン誘導体および使用方法
BR112020021728A2 (pt) 2018-04-27 2021-01-26 Shionogi & Co., Ltd. derivados de tetra-hidropiranooxazina tendo atividade inibitória de bace1 seletiva
CN109725092A (zh) * 2019-03-19 2019-05-07 北京和合医学诊断技术股份有限公司 检测血液中齐拉西酮含量的液相色谱分析方法
CN113173852B (zh) * 2021-04-26 2022-07-12 深圳市华先医药科技有限公司 二氟丙二酸酯类化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6911868A (es) 1968-08-31 1970-03-03
WO2003006426A1 (en) * 2001-07-13 2003-01-23 Axxima Pharmaceuticals Ag Aromatic guanylhydrazones as effective compounds against neurodiseases
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AR044399A1 (es) 2003-05-20 2005-09-14 Novartis Ag Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
ES2476027T3 (es) 2005-10-25 2014-07-11 Shionogi & Co., Ltd. Derivados de aminodihidrotriazina
ES2476605T3 (es) * 2007-04-24 2014-07-15 Shionogi & Co., Ltd. Derivados de aminohidrotiazina sustituidos con grupos cíclicos
WO2008133273A1 (ja) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. アルツハイマー症治療用医薬組成物
JPWO2010047372A1 (ja) * 2008-10-22 2012-03-22 塩野義製薬株式会社 Ｂａｃｅ１阻害活性を有する２−アミノピリミジン−４−オンおよび２−アミノピリジン誘導体
WO2010063718A1 (en) 2008-12-02 2010-06-10 ETH Zürich Screening assay for metabolic disease therapeuticals
US8461160B2 (en) * 2009-05-08 2013-06-11 Hoffmann-La Roche, Inc. Dihydropyrimidinones
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US7964594B1 (en) 2009-12-10 2011-06-21 Hoffmann-La Roche Inc. Amino oxazine derivatives
US8999980B2 (en) 2009-12-11 2015-04-07 Shionogi & Co., Ltd. Oxazine derivatives
UA103272C2 (uk) 2009-12-11 2013-09-25 Ф. Хоффманн-Ля Рош Аг 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EP2663308A1 (en) 2011-01-13 2013-11-20 Novartis AG Bace-2 inhibitors for the treatment of metabolic disorders
US8426584B2 (en) 2011-01-21 2013-04-23 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of fused aminodihydrothiazine derivatives
US8404680B2 (en) 2011-02-08 2013-03-26 Hoffmann-La Roche Inc. N-[3-(5-amino-3,3a,7,7a-tetrahydro-1H-2,4-dioxa-6-aza-inden-7-yl)-phenyl]-amides as BACE1 and/or BACE2 inhibitors
US8754075B2 (en) 2011-04-11 2014-06-17 Hoffmann-La Roche Inc. 1,3-oxazines as BACE1 and/or BACE2 inhibitors
TW201247635A (en) 2011-04-26 2012-12-01 Shionogi & Co Oxazine derivatives and a pharmaceutical composition for inhibiting BAC1 containing them
US8785436B2 (en) 2011-05-16 2014-07-22 Hoffmann-La Roche Inc. 1,3-oxazines as BACE 1 and/or BACE2 inhibitors
EP2718287A1 (en) 2011-06-07 2014-04-16 F.Hoffmann-La Roche Ag [1,3]oxazines
CA2837252A1 (en) 2011-06-07 2012-12-13 F. Hoffmann-La Roche Ag Halogen-alkyl-1,3 oxazines as bace1 and/or bace2 inhibitors

Also Published As

Publication number Publication date
EP3023423A1 (en) 2016-05-25
EP2748162A1 (en) 2014-07-02
SG2014012108A (en) 2014-05-29
MA35356B1 (fr) 2014-08-01
EA201490491A1 (ru) 2014-06-30
JP2014524463A (ja) 2014-09-22
US20150150877A1 (en) 2015-06-04
ZA201401139B (en) 2014-12-23
PL2748162T3 (pl) 2016-06-30
CO6890097A2 (es) 2014-03-10
MX2014002230A (es) 2014-04-25
WO2013027188A1 (en) 2013-02-28
AU2012298177B2 (en) 2015-10-29
CN103906748A (zh) 2014-07-02
IL230975A0 (en) 2014-03-31
TW201313706A (zh) 2013-04-01
EA024580B1 (ru) 2016-09-30
US9163011B2 (en) 2015-10-20
TN2014000062A1 (en) 2015-07-01
JP5816369B2 (ja) 2015-11-18
AP2014007507A0 (en) 2014-03-31
ES2565229T3 (es) 2016-04-01
AR087668A1 (es) 2014-04-09
EP3023423B1 (en) 2017-05-31
CN103906748B (zh) 2017-06-16
US20130172331A1 (en) 2013-07-04
NZ621093A (en) 2015-05-29
UY34278A (es) 2013-04-05
ES2638832T3 (es) 2017-10-24
HK1195903A1 (en) 2014-11-28
CL2014000458A1 (es) 2014-09-05
AU2012298177A1 (en) 2014-03-06
KR20140054313A (ko) 2014-05-08
CA2845093A1 (en) 2013-02-28
KR101601571B1 (ko) 2016-03-08
EP2748162B1 (en) 2015-12-16
CR20140084A (es) 2014-05-02
BR112014004131A2 (pt) 2017-06-13
MX339303B (es) 2016-05-19
PE20141540A1 (es) 2014-10-31

Similar Documents

Publication Publication Date Title
GT201400031A (es) Derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina y su uso como inhibidores de bace-1 y/o bace-2
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
BR112016015838A8 (pt) compostos heterocíclicos aromáticos, composição farmacêutica compreendendo os referidos compostos e produto de combinação
PE20151067A1 (es) Inhibidores de autotaxina
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP12011622A (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
EA201490774A1 (ru) Новые производные оксазина и их применение при лечении заболевания
CR20160518A (es) Compuestos para tratar atrofia muscular espinal
UY32848A (es) Compuestos heterocíclicos de oxima
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CO6781507A2 (es) Novedosos derivados heterociclicos
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
ECSP17026748A (es) Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos
CR20150378A (es) Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
UY33655A (es) Co-cristales y sales de inhibidores de ccr30
ECSP11010992A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer